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ABSTRACT Confocal spectral imaging (CSI) technique was used for quantitative analysis of the uptake, subcellular
localization, and characteristics of localized binding and retention of anticancer agent mitoxantrone (MITOX) within human
K562 erythroleukemia cells. The CSI technique enables identification of the state and interactions of the drug within the living
cells. Utilizing this unique property of the method, intracellular distributions were examined for monomeric MITOX in polar
environment, MITOX bound with hydrophobic cellular structures, naphthoquinoxaline metabolite, and nucleic acid-related
complexes of MITOX. The features revealed were compared for the cells treated with 2 ,uM or 10 ,uM of MITOX for 1 h and
correlated to the known data on antitumor action of the drug. MITOX was found to exhibit high tendency to self-aggregation
within intracellular media. The aggregates are concluded to be a determinant of long-term intracellular retention of the drug
and a source of persistent intracellular binding of MITOX. Considerable penetration of MITOX in the hydrophobic cytoskeleton
structures as well as growing accumulation of MITOX bound to nucleic acids within the nucleus were found to occur in the
cells treated with a high concentration of the drug. These effects may be among the factors stimulating and/or accompanying
high-dose mitoxantrone-induced programmed cell death or apoptosis.
INTRODUCTION
Mitoxantrone (Novatrone>'), a synthetic anthraquinone
drug (for structure, see Feofanov et al., 1997b), shows
considerable promise as an antitumor agent in treatment of
acute nonlymphocytic leukemia, advanced breast cancer,
and non-Hodgkin's lymphomas (Arlin et al., 1990; Ehnin-
ger et al., 1990; Faulds et al., 1991). A pharmacological
effect of mitoxantrone (MITOX) is suggested to be closely
related to its ability to bind with DNA. Few mechanisms of
MITOX action involving formation of MITOX-DNA com-
plexes have been proposed, including trapping of the topo II
complex (Smith et al., 1990; D'Agra and Liu, 1989; Corbett
and Osheroff, 1993) and aggregation and compaction of
chromatin (Kapuscinski and Darzynkiewicz, 1986). It
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should be mentioned that topo II, a nuclear enzyme, is an
essential part of a human cell's replication and transcription
machinery (Wang, 1996). The recent results demonstrating
that DNA topoisomerases are intracellular targets for a wide
variety of known and emerging antitumor drugs appear to
be among the most important discoveries in cancer research
over the last three decades (Capranico and Zunino, 1995).
The DNA-MITOX-topo II cleavable complex is a reversible
molecular event, but it leads to cell death probably due to
ongoing DNA-dependent processes, which may be the trig-
ger of the cell death program.
Another type of DNA damage arises probably from for-
mation of free radicals by MITOX (Basra et al., 1985).
Besides DNA, MITOX binds to cytoplasmic structures
(Roberts et al., 1989), and inhibition of microtubule assem-
bly has been suggested to be a possible mechanism of the
drug action at high concentrations (Ho et al., 1991).
Cytotoxicity of MITOX in HepG2 cells and in rat hepa-
tocytes has been shown to be defined by the metabolites
rather than by MITOX itself (Mewes et al., 1993). Since
MITOX readily undergoes oxidation catalyzed by horserad-
ish peroxidase (HRP) and cytochrome P-450 (Mewes et al.,
1993; Reszka et al., 1986; Wolf et al., 1986), the cytotoxic
action of the drug metabolites derived from oxidation by the
cellular enzymes may appear as a general effect in other
cells, particularly in the transformed human fibroblasts.
Recently, a high concentration of MITOX (between 0.1 and
10 ,uM) was found to induce the programmed cell death
(PCD) or apoptosis in leukemic cells (Bhalla et al., 1993).
The data cited above demonstrate that a number of mecha-
nisms can support antitumor activity of MITOX, and the
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relative contribution of each to the overall effect of the drug
needs to be clarified at the different regimes of cell treat-
ment with MITOX.
To shed light on roles of different mechanisms and bio-
logical targets in the pharmacological action of MITOX, the
CSI technique was introduced to the noninvasive study of
the drug uptake, distribution, and interactions in intact,
viable cells (Sharonov et al., 1994; Feofanov et al., 1997b.
The technique was shown to be complementary to conven-
tional flow cytometry and laser scanning confocal fluores-
cence microscopy methods. The CSI technique is based on
the analysis of a 2D set of spectra recorded from within
drug-treated cells with -0.5-1.5 ,um3 spatial resolution. It
enables different states and interactions of the drug to be
traced and mapped within the cell. The CSI technique
allows intrinsic cellular fluorescence and enhancement'
quenching of fluorescence of the drug localized in different
states to be accounted for, and this is very important for
correct quantitative analysis. Four different states of MI-
TOX were identified and mapped within living K562 cells
by means of the CSI technique (Feofanov et al., 1997b):
MITOXmono, MITOXphob, MITOXNA, and NQX metabolite
(for structure, see Feofanov et al., 1997b).
This report describes the quantitative analysis of the
uptake of MITOX in human K562 erythroleukemia cells
exposed to 2 ,uM and 10 ,uM of MITOX for 1 h. Quan-
titative distributions of MITOXmono, MITOXphob, and
MITOXNA and relative distributions of the intrinsic cellular
fluorescence and NQX metabolite within intracellular com-
partments are mapped, and the sites of heterogeneous accu-
mulation of the drug are characterized. Averaged intracel-
lular concentrations and the patterns of intracellular
distributions of MITOXmono, MITOXphob, and MITOXNA
as a function of extracellular concentration of the drug are
analyzed. Increased aggregation of MITOX within the cell
in relation to aqueous buffer environment was observed.
Accordingly, the majority of the drug molecules were found
to accumulate in cytoplasmic compartments in an aggre-
gated form. The features of localized binding and retention
of MITOX observed by the CSI technique within human
K562 erythroleukemia cells are correlated to the data on
antitumor activity of the drug.
MATERIALS AND METHODS
Reagents and Cells
Stock solution (0.1 mM) of MITOX (Lederle Laboratories, Rungis, France)
was prepared in PBS. Concentration of MITOX in aqueous buffer solutions
was measured by absorption at the isosbestic point at Ai = 682 nm using
extinction coefficient EAi = 8.36 x 103 M-1 cm- (Kapuscinski et al.,
1981). All other chemicals were of analytical-reagent grade and all solvents
were of HPLC grade.
K562 is a human erythroleukemic cell line, established from a patient
with chronic myelogeneous leukemia in blast transformation. The cells
were grown exponentially at 3-7 x 105 cells/ml in RPMI-1640 (Gibco,
Grand Island, NY) containing 10% fetal calf serum (Seromed) and 2 mM
L-glutamsne (Sigma).
The cells were incubated in the presence of 10-9-10-6 M MITOX for
1 h. The cells were washed twice, resuspended with fresh media, and
counted after mixing with 0.2% trypan blue. The IC50 was determined by
plotting the number of viable cells as a percentage of the control against the
drug concentration. All cytotoxicity assays were repeated three times. The
drug IC50 was determined to be 30 + 14 nM for the K562 cells.
To quantify the drug within the cells the DMSO extraction procedure
was applied. After incubation with MITOX (10 ,tM of the drug for 1 h or
2 ,uM for 1 h) the cells (5 ml at 7 x 105 cells/ml) were rinsed two times
with PBS and centrifuged at 180 x g for 5 min. The supermatant was
removed and pellet was resuspended in 200 ,ul of DMSO for 20 min in
order to extract MITOX. Afterward, the cells' homogenate was centrifuged
at 180 x g for 5 min, and the drug-contained supernatant was collected.
The concentration of the drug in supermatant was determined by absorption.
Average intracellular concentration of the drug was calculated assuming
the average diameter of cells to be 17 + 3 ,gm. The average diameter of the
cells was measured with a light microscope. For CSI measurements the
cells treated with MITOX were rinsed twice with PBS, resuspended in the
fresh PBS solution, and placed under the microscope.
Spectral measurements
Feofanov et al. (1997b) describe the instrumentation for CSI measurements
as well as details of acquisition and treatment of spectral images. Each
experimental spectrum recorded from a cell was decomposed as a sum of
the reference spectra with appropriate coefficients. 2D maps of decompo-
sition coefficients (hereafter referred to as spectral images) reflect relative
distribution along the specimen of each component which spectrum was
introduced as a reference.
Feofanov et al. (1997b) define the basic set of the reference spectra
originated from in vitro modeling measurements. This set of spectra
includes: (i) the spectrum of monomeric MITOX in aqueous environment;
(ii) the spectrum of MITOX in propanol; (iii) the spectrum of MITOX-
DNA complex; (iv) the spectrum of the NQX metabolite in dioxane; and
(v) the spectrum of intrinsic cellular fluorescence. Spectrum (i) is assigned
to MITOXmono; spectrum (ii) is assigned to MITOXphob; spectrum (iii) is
considered to describe three types of complexes within the cells that cannot
be spectrally distinguished, namely, MITOX-DNA complexes, ternary
complexes between MITOX, DNA, and topo H, as well as ds MITOXNA.
Spectrum (iv) is assigned to the NQX metabolite bound to the acceptor
groups of cellular structures or molecules.
Quantitative analysis of mitoxantrone
intracellular concentration
The calibration procedures have been performed to estimate subcellular
concentration of MITOXmono, MITOXPhob, and MITOXNA based on in-
tensity of the corresponding microfluorescence spectra. The spectra of
monomeric MITOX in the aqueous buffer, MITOX in propanol and the
spectra of the solution of MITOX-DNA complexes were measured as a
function of the drug concentration under the microscope at the experimen-
tal conditions (lateral and axial resolution, laser power, amplitude of the
scanning laser beam, integration time, etc.) used for recording the confocal
spectral images. The calibration curves were obtained. To quantify the drug
in these three states, a 2D set of the spectra measured from the cell was
decomposed into components corresponding to the set of reference spectra,
and fluorescence intensities of the corresponding components were recal-
culated into concentrations based on results of the calibration procedure.
As was shown previously, concentration-dependent formation of mi-
toxantrone dimers is accompanied by fluorescence quenching (Feofanov et
al., 1997b). The amount of nonfluorescent MITOXdi within the cells was
estimated assuming that 1) the equilibrium constant of MITOX dimeriza-
tion (Kd) in intracellular aqueous environment is the same as in aqueous
buffer, and 2) the sites of intracellular accumulation of the monomeric and
dimeric MITOX coincide. This estimation was based on the equation
[MITOXdi]= 2Kd X [MITOXmono]2 (1)
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where [MITOXdi1 is a concentration of MITOX molecules in dimeric state,
[MITOXmono] is a concentration of monomeric MITOX, and Kd = 3 x 104
m ' (Kapuscinski and Darzynkiewicz, 1985).
The average concentrations of each component (MITOXmono, MI-
TOXphob, MITOXNA, and MITOXdi) within the cytoplasm and the nucleus
of K562 cells were calculated basing on confocal spectral images measured
at the equatorial optical section of the cells. To calculate the total average
intracellular concentration of MITOX (Ccell) on the basis of CSI measure-
ments, the equation
Ccell = Cnuc(Vnuc/Vcell) + Ccyt(Vcyt/Vcell) (2)
is introduced, where Cnuc and Ccy, are the total average concentrations of
MITOX in the nucleus and cytoplasm, respectively, including MITOXmOno,
MITOXPhOb, MITOXNA, and MITOXdi states; Vnuc, Vcyt, and Vcell are the
volumes of nucleus, cytoplasmic region, and the cell as a whole, respec-
tively. A relative volume of the nucleus (VnujVcel) was estimated by
approximating the shapes of the cell and nucleus by spheres. Then
(Vnuc/vcell) = (Snuc/scell)3/2 (3)
and
(Vcyt/Vcell) = 1 - (Snuc/Scell)3/2 (4)
where Snuc and SceIl are the areas of the nucleus and cell, respectively, at the
equatorial section. These areas were measured using recorded spectral
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images, and, finally, Ccell was calculated for each scanned cell as
Ccell = Cnuc(Snu Scell) + Ccyt[ (SnuScell) 3/2] (5)
Assuming that 1) the cells attached to the plastic change from a spherical
shape to an ellipsoidal one with the axis c, less than ax = by, and 2) the cell
and its nucleus undergo similar attachment-induced deformation (the ratios
cJlax for the cell as a whole and for the nucleus are equal), we come up with
exactly the same Eq. 5.
It should be mentioned that like many other cells, the K562 cells tend
to adopt the quasispherical shape in suspension. SCI measurements were
performed during the next 10-20 min after the cells were resuspended (see
Experimental section). Obviously, the cells just resuspended were not so
tightly attached on the plastic to sprawl and to change considerably initially
spherical or ellipsoidal shape. As examined with the optical microscope,
the freshly attached K562 cells have circular cross-sections (ax = by) and
the average diameter of the attached cells is increased only slightly as
compared with the cells in suspension (small attachment-induced defor-
mation). Therefore, our assumption on the shape of the cell appears
reasonable in estimating intracellular concentration of MITOX.
Averaged over 30 cells, the area of nucleus at the equatorial section was
measured to be 43 ± 9% of the cell area. Assuming the shapes of both cell
and nucleus are spherical (or ellipsoidal), the volume of nucleus was
estimated to be 28 ± 9% of the cell volume.
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FIGURE 1. Confocal spectral images of two typical cells (I and IH) exposed to 10 p,M MITOX for 1 h. Conventional light-microscope image of the cell
(a). Localization of intrinsic cellular fluorescence (b). Spectral images describing the subcellular distribution of monomeric MITOX in the polar
environment (c), nucleic acid related complexes of MITOX (d), MITOX bound within hydrophobic cellular structures (e) as well as NQX metabolite bound
to the ligands (f). Scales are independent of each other and show the concentration of MITOX in ,uM for the images (c, d, e) as well as the relative intensity
of signal in arbitrary units for the images (b, f). Bar shown on the image (a) corresponds to 2 jum.
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RESULTS
Localization, state, and interactions of
mitoxantrone in the K562 cells
Confocal spectral images of cells after exposure to 10 ,uM
of MITOX for 1 h as well as cells after treatment with 2 ,uM
MITOX for 1 h are shown in Figs. 1 and 2, respectively.
These images describe 2D quantitative distribution of mo-
nomeric MITOX in MITOXmono, MITOXphob, MITOXNA,
and relative distribution of the NQX metabolite and intrinsic
fluorescence of the cells along the equatorial optical section.
According to our previous study (Feofanov et al., 1997b),
MITOXmono is the monomeric drug molecules localized in
a polar (aqueouslike) intracellular environment. They may
be either free or bound through the alkylamino side chains
to cellular molecules. Such interactions, which involve the
side chains but not the chromophore moiety of MITOX, do
not affect fluorescence of the drug and thereby cannot be
discriminated. MITOXphOb is the drug molecules involved
in forced hydrophobic contacts and/or the molecules having
the chromophore moiety in a nonpolar environment due to
binding of the drug within the hydrophobic cellular struc-
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tures. MITOXNA is referred to as the molecules bound with
ds fragments of RNA, ds DNA alone, or within ternary
complexes between MITOX, DNA, and topo II. These three
types of complexes are characterized by a similar mode of
interaction; that is, intercalation of the MITOX chro-
mophore in ds helix of DNA or RNA, and, showing similar
fluorescence spectra, cannot be spectrally distinguished
within the cells. The features of fluorescence of the NQX
metabolite in a cellular environment indicate that it is bound
to the acceptor groups of cellular molecules (Feofanov et
al., 1997b). The parameters of the reference spectra corre-
sponding to MITOXmono, MITOXphob, MITOXNA, and
bound NQX metabolite are listed in Table 1.
MITOX undergoes concentration-dependent formation of
dimers (Kapuscinski and Darzynkiewicz, 1985). Dimeric
MITOX does not fluoresce (Feofanov et al., 1997b) and
cannot be measured in cells by CSI. Nevertheless, due to an
inherent property ofMITOX to aggregate, it is reasonable to
suggest that dimeric MITOX is co-distributed with free
MITOXmono within the cell.
Distributions of MITOX and its complexes are quite
heterogeneous within the cell. MITXmonoX MITOXphob,
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FIGURE 2. Confocal spectral images of the two typical cells (I and II) exposed to 2 ,uM MITOX for 1 h. Conventional light-microscope image of the
cell (a). Localization of intrinsic cellular fluorescence (b). Spectral images describing subcellular distribution of monomeric MITOX in the polar
environment (c), nucleic acid related complexes of MITOX (d), MITOX bound within hydrophobic cellular structures (e) as well as NQX metabolite bound
to the ligands (f ). Scales are independent of each other and show the concentration of MITOX in ,uM for the images (c, d, e) as well as the relative intensity
of signal in arbitrary units for the images (b, f). Bar shown on the image (a) corresponds to 2 ,um.
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TABLE I Spectral parameters of the absorption and
fluorescence spectra used as models for the analysis of
interactions of mitoxantrone and its naphtoquinoxaline
metabolite in the K562 cells
Absorption Fluorescence*
Amax I Ama2 AmaxC FWHM§
Models (nm) (nm) RA# (nm) (nm) Irel1
1MITOXmono 610 661 1.34 685 58 1.0
**MITOXphob 623 675 1.34 694 46 2.1
#*MITOXNA 628 680 1.34 700 50 0.65
§§Bound NQX 588 636 1.2 652 36
*Intensities were corrected for the effect of inner filter. Excitation wave-
length, 514.5 nm.
#Ratio of absorbance at Amax2 to that at Amaxi.
§Full width of spectrum at the half of maximum.
qRelative intensity as compared with the intensity of equimolar aqueous
solution of monomeric MITOX.
IMonomeric MITOX in polar intracellular environment.
**MITOX bound within hydrophobic cellular structures.
W*MITOX-DNA, MITOX-DNA-topo II, and MITOX-RNA complexes.
§§NQX metabolite of MITOX bound with acceptor groups of molecules in
the cell.
and NQX metabolite accumulate in cytoplasm, whereas
MITOXNA dominates within the nucleus (Figs. 1 and 2;
Table 2). The intrinsic cellular fluorescence intensity also
varies with different cellular compartments (Figs. 1 and 2).
It is exceptionally observed from within cytoplasm and has
a maximum in the regions adjacent to the nucleus. A qual-
itative pattern of the intrinsic fluorescence was found to be
similar for control and MITOX-treated cells (Feofanov et
al., 1997b).
MITOXNA stains the perinucleolar region and accumu-
lates in nucleolarlike bodies at concentrations comparable
(Fig. 1) and even higher (Fig. 2) than peak concentrations of
the MITOXmono and MITOXphob in cytoplasm. The average
concentration of MITOXNA in nucleolarlike bodies is -2-
fold higher than that in the perinucleolar compartments
(Table 2). The presence of MITOXmono and MITOXphob is
observed in perceptible amounts along the boundary regions
of the nucleus (Figs. 1 and 2; Table 2), where the thickness
of the nucleus is less than axial resolution (-3 ,um) of the
confocal scanning system. These drug molecules are located
on or close to the nucleus membrane rather than within the
nucleus, as proved by 3D analysis of MITOX distribution
within the cell (Feofanov et al., 1997b).
The patterns of subcellular distribution of MITOXmono
and the NQX metabolite are similar at the both regimes of
cell treatment (Figs. 1 and 2). In addition to uniformly
stained cytoplasm, MITOXmono and the NQX metabolite are
accumulated in a compact region adjacent to the nucleus.
The peak concentrations of MITOXmono observed in this
region are -2.5-fold higher than in the peripheral cyto-
plasm. The regions of concentrated MITOXmono and the
NQX metabolite coincide with the sites of intense intrinsic
fluorescence of the cell (Figs. 1 and 2).
It should be mentioned that the NQX metabolite fluo-
resces much more intensely as compared to an equimolar
solution of MITOX at the 514.5 nm excitation used for CSI
measurements. Since the NQX metabolite hardly contrib-
utes to an overall intracellular fluorescent signal (Feofanov
et al., 1997b), its concentration in the cells is inferred to be
rather small. Therefore, we do not perform quantitative
analysis here and report only on relative distribution of the
NQX metabolite in the cells.
The pattern of MITOXphob distribution was found to
differ from the patterns observed for both MITOXmOno and
the NQX metabolite, and it depends on the drug concentra-
tion used to treat the cells. MITOXphob is enfolded in small
cytoplasmic inclusions (Fig. 2, le) which tend to group close
to the nucleus (Fig. 2, HIe) in the cells exposed to 2 ,uM
of MITOX. In opposite, besides small inclusions of
MITOXphob, general staining of hydrophobic cellular struc-
tures appears in the cytoplasm of the cells treated with 10
,uM of the drug (Fig. 1, Ie, lIe). It is noteworthy that we
have not attempted yet to identify the origin of either of
these inclusions or stained hydrophobic cellular structures at
the present stage of the study.
Concentration-dependent accumulation and
distribution of mitoxantrone in the cells
The average intracellular concentrations of MITOX have
been defined for both 10 ,um X 1 h and 2 ,um X 1 h regimes
of cell treatment by means of both the CSI technique and
DMSO extraction as described in Materials and Methods
(Table 3). The concentrations calculated by the CSI analysis
are obviously underestimated as compared to the DMSO
extraction data. This deviation is likely due to intrinsic error
in estimating concentration of dimeric MITOX by the CSI
technique. The only concentration of fluorescent MITOX
can be directly assayed by CSI. The concentration of fluo-
rescent MITOX does not exceed 30% of total intracellular
concentration determined by the DMSO extraction. There-
fore, the rest of the intracellular drug is assumed to be
related to the nonfluorescent aggregates of MITOX. At the
same time, subcellular concentration of dimeric MITOX
calculated by the CSI technique on the basis of distribution
of MITOXmono and Kd = 3 X 104 m- 1 (as in aqueous buffer
solution (Kapuscinski and Darzynkiewicz, 1985)) led us to
a considerably lower value (Table 2). This value becomes
even lower assuming that part of MITOXmono bound
through alkylamino side chains to cellular molecules is not
concerned with free monomeric MITOX equilibrated with
dimeric MITOX. Thus, one may suggest advanced aggre-
gation of MITOX within the cells.
Finally, combining the results obtained by the DMSO
extraction with the CSI analysis data it can be concluded
that -70% of intracellular MITOX is accumulated in the
cytoplasmic region in the aggregated form. The cellular
uptake of MITOX is very high, exceeding -80-fold the
extracellular concentration of the drug and does not exhibit
a saturation even at the 10 ,uM X 1 h regime of cell
treatment.
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TABLE 2 Average subcellular concentration of mitoxantrone (mean + SE) in different states and complexes in K-562 cells as
estimated by confocal spectral imaging analysis
10 t.M x 1 h Dose of Treatment 2 /LM X 1 h Dose of Treatment
Average Concentration of Mitoxantrone Average Concentration of Mitoxantrone
State of Perinucleolar Perinucleolar
Mitoxantrone Cytoplasm Nucleus Nucleoli region Cytoplasm Nucleus Nucleoli region
in the Cells (wM) (,.M) (AM) (/.M) GLM) (QiM) (wM) (AM)
MITOX-DNA* 11 + 7 270 + 170 410 + 150 203 + 135 2.1 ± 1.5 45 ± 24 64 + 21 35 + 18
MITOXphob# 54 + 36 31 + 22 2.9 + 1.7 4 + 2
MITOXmonot 75 + 47 22 + 12 23 ± 14 13 + 6
MITOXdimer 352 + 280 44 + 26 43 + 21 16 + 12
*MITOX-DNA, MITOX-DNA-topo II, and MITOX-RNA complexes.
#MITOX bound within hydrophobic cellular structures.
§Monomeric MITOX in polar intracellular environment.
qDimers of MITOX. It was calculated from distribution of monomeric MITOX assuming the equilibrium constant of dimerization Kd
(Kapuscinski and Darzynkiewicz, 1985).
3 X 104 M-1
The relative concentrations of MITOXNA in the nucleus
are 0.34 and 0.28 of average intracellular concentrations at
the 10 ,um X 1 h and 2 ,um X 1 h treatments, respectively.
So, MITOX penetrates in the nucleus and complexes with
nucleic acids proportionally to extracellular concentration
of the drug. The absence of saturation even at the 10 ,um X
1 h cell treatment is typical for this process. Preferential,
-2-fold higher, localization of MITOXNA within the nucle-
oli as compared to the perinucleolar region is retained at
both 2 ,uM and 10 ,uM extracellular concentrations of
MITOX (Table 2).
Relative cytoplasmic concentrations of MITOXphob are
equal to 0.07 and 0.02 of average intracellular concentra-
tions at the 10 ,um X 1 h and 2 ,um X 1 h treatments,
respectively. The concentrations of MITOXphob and MI-
TOXmono become comparable (Table 2), and general stain-
ing of hydrophobic cellular structures appears (Fig. 1) at the
10 ,um extracellular concentration of MITOX. It clearly
indicates concentration-dependent enhancement of the drug
penetration in and/or binding within hydrophobic cellular
structures. No such an effect in respect to the cellular
membrane is distinctly observed. At the same conditions
relative cytoplasmic concentration of MITOXmono falls
from 0.14 to 0.095 of average intracellular concentrations,
demonstrating moderate concentration-dependent satura-
tion. This saturation occurs probably due to both more
strong capture of the drug in hydrophobic structures and
TABLE 3 Intracellular concentration of mitoxantrone
calculated on the basis of CSI analysis (mean + SE) and
measured by DMSO extraction for two regimes of cell
treatment by the drug
Intracellular Concentration of the Drug
(/M) According to
Dose of Treatment CSI Analysis DMSO Extraction
10 ZM for 1 h 456 ± 240 790 ± 360
2jM for 1 h 72 ± 38 162 ± 75
enhanced aggregation of MITOX within the cells exposed
to 10 ,tM of the drug.
DISCUSSION
The quantitative analysis of uptake and distribution of MI-
TOX within the K562 cells was performed by utilizing the
unique ability of CSI technique to characterize state and
interactions of MITOX within intact, living cells. The goal
of the study is to find an approach to clarify relative contribu-
tions of different mechanisms of antitumor action reported for
MITOX. In this way we are going to combine conventional
biochemical and cytological methods with noninvasive quan-
titative CSI analysis. As the first step we attempt to character-
ize by CSI technique the features of MITOX interactions and
distribution within living K562 cells in order to find correlation
with known biochemical data on accumulation and activity of
MITOX in cancer cells.
Features of mitoxantrone accumulation within
the cells
The quantitative CSI analysis combined with the DMSO
extraction procedure shows that intracellular MITOX con-
centration exceeds -80-fold its extracellular concentration
in the human erythroleukemic K562 cells exposed to 2 AM
and 10 AM of MITOX for 1 h (Table 3). Appearance of the
drug within different cellular compartments was observed
during the first 20 min of incubation, demonstrating fast
cellular uptake of MITOX. In contrast, the active efflux of
MITOX was found to be less efficient.
These findings are in general accordance with the data on
dynamics of the cellular uptake of MITOX. Intracellular
concentration of the drug exceeded -240-fold the extracel-
lular one when the human colon carcinoma WiDr cells were
exposed to 1.9 ,tM ofMITOX for 1 h (Wallace et al., 1987).
Appearance of the drug within different cellular compart-
ments of the WiDr cells (Roberts et al., 1989) and SV40
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transformed human MRC5CVI fibroblasts (Smith et al.,
1992) was observed at the same time scale as for the K562
cells. Long-term intracellular retention of MITOX was re-
ported for the WiDr cells (Roberts et al., 1989; Wallace et
al., 1987), MRC5CVI cells (Smith et al., 1992; Fox and
Smith, 1990) and for lBr3gn2, GM0637, AT5BIVA, NEl-
3/48 cells (Fox and Smith, 1990). The drug retention was
suggested to be an important determinant of the MITOX
action resulting in G2 cell cycle arrest and cellular damage.
In this study the drug was revealed to accumulate heter-
ogeneously within cytoplasm in the forms of monomeric
MITOX exposed to polar intracellular environment, MI-
TOX bound within hydrophobic cellular structures, and
aggregated MITOX. Metabolization of MITOX results in
formation of the NQX metabolite. MITOXmono is a free
drug or drug bound through alkylamino side chains to
cellular molecules. Its relative concentrations in cytoplasm
are 0.095 and 0.14 of the average intracellular concentra-
tions at the 10 ,tM X 1 h and 2 ,uM X 1 h cell treatments,
respectively. The relative concentrations of MITOXphob in
cytoplasm are equal to 0.07 and 0.02 at the 10 ,tM X 1 h
and 2 ,uM X 1 h cell treatments, respectively.
The aggregation of MITOX was concluded to increase in
an intracellular medium as compared to an aqueous buffer
environment, and the majority (-70%) of the accumulated
drug was found to be aggregated. This intracellular aggre-
gated drug is not directly involved in the drug-target inter-
actions, but on dissociation the aggregates can be a source
for continually reforming the drug-target complexes. One
may suppose that long-term inhibition of DNA synthesis
and persistence of the trapped topo II complexes (Fox and
Smith, 1990) result (at least partially) from long-term main-
tenance of the cytotoxic concentration of MITOX due to
slow dissociation of aggregates in response to the efflux of
the monomeric drug. This conclusion is also confirmed by
the data of a biochemical fractionation procedure (Roberts
et al., 1989) which revealed that 1) a principal part of
MITOX in the cells exposed to 50 ,uM for 1 h is associated
with the cytoplasmic fraction, and 2) further incubation (up
to 72 h) of cells in a drug-free medium is accompanied by
a decrease in the relative amount of MITOX in the cyto-
plasmic fraction, while the drug content in the fraction
enriched by DNA and RNA relatively increases.
The CSI analysis revealed that accumulation of MITOX
within the nucleus occurs 1) proportionally to the extracel-
lular concentration of the drug, 2) at the average concen-
tration -24-fold exceeding its extracellular value, 3) at
-2-fold higher concentration in the nucleoli than in the
nucleoplasm, 4) without saturation up to 10 ,uM for 1 h
dosage of cell treatment, and 5) predominantly in the form
of the drug complexes with ds nucleic acids.
The origin of intrinsic cellular fluorescence and
preliminary assignments of the sites of
cytoplasmic localization of mitoxantrone
While more detailed studies based on simultaneous treat-
ment of cells with MITOX and selective labeling of cellular
organelles will be the subject of a separate publication, we
discuss here preliminary assignments of the sites of cyto-
plasmic localization of the drug.
The spectra of intrinsic fluorescence of the K562 cells
excited at 514.5 nm are quite broad. They exhibit two
overlapped maxima at 640 and 652 nm and a shoulder at
-700 nm (Feofanov et al., 1997b). The cellular fluores-
cence in the red was shown to correspond to porphyrins
(Udenfreid, 1965; Gurinovich et al., 1968; Maneshin and
Arevshatian, 1972). Luminescence features of different por-
phyrins (copro, uro, meso, aetio, and hematoporphyrins) are
very similar: major band, 625 nm; y, 654 nm; ,3, 673 nm; a,
691 nm (Udenfreid, 1965). The fluorescence spectrum of
protoporphyrin IX has maxima at 635 nm and 703 nm and
strongly depends on environmental conditions (Gurinovich
et al., 1968). On adding glycerin to the ethanol solution of
protoporphyrin a new band appears at 676 nm, whereas
intensity of the 635 nm band decreases and the 703 nm band
becomes a weak shoulder (Gurinovich et al., 1968). Evi-
dently, overlapping of the signals of several porphyrins
located in different microenvironments determines the spec-
tra observed from the K562 cells. Accumulation of porphy-
rins in the cells was assigned to functioning of the enzymes
of respiratory chain involved in the transfer of electrons
(Maneshin and Arevshatian, 1972). Mitochondria are be-
lieved to be the principal sites of porphyrin accumulation.
Therefore, intrinsic fluorescence of cells in the red region
may be considered as a natural fluorescent marker of
mitochondria.
The results of the CSI analysis show that the regions of
concentrated MITOXmono and NQX metabolite coincide
with the sites of intense intrinsic cellular fluorescence (Figs.
1 and 2). Though the resolution achieved is not enough to
assert if the drug and its metabolite are localized within
mitochondria, at least the proximity of the sites of both
preferential accumulation of the drug and its metabolization
to the mitochondrial system seem to be obvious. In accor-
dance with the data published before (Wolf et al., 1986;
Blanz et al., 1991; Kolodziejczyk et al., 1988) one may
conclude that the NQX metabolite originates from oxidative
action of cellular enzymes. As revealed by CSI analysis, it
is bound to the acceptor groups of some ligands within the
cells.
Considerable accumulation of MITOX (up to 7%) ac-
companied by pronounced change in the pattern of its
distribution was detected within hydrophobic cytoplasmic
cellular structures by the CSI technique when extracellular
drug concentration increased from 2 to 10 pkM (Tables 2 and
3). Previously, by using the biochemical fractionation pro-
cedure, -10% of the persistent drug binding was found to
be associated with water insoluble cytoskeleton fraction
within the WiDr cells (Roberts et al., 1989). Cytokeratin and
lamin intermediate filaments were identified as dominant
proteins in the cytoskeleton fraction. It has been also re-
ported (Ho et al., 1991) that MITOX plays a role of a
microtubule inhibitory agent and can exert its intracellular
effect through modulation of microtubule assembly. Poly-
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merization of tubulin was found to be inhibited in the
presence of 2 to 10 ,M of MITOX in proportion to dosage.
Each time when the effect of MITOX on hydrophobic
proteins and/or cellular structures was observed, the cells
were exposed to high concentrations of MITOX: 2-10 ,uM
(Ho et al., 1991), and 50 ,uM (Roberts et al., 1989). There-
fore, one may assume that concentration-dependent changes
in the pattern of accumulation and distribution of
MITOXphob observed by the CSI technique manifest the
appearance of MITOX binding within hydrophobic, most
probably cytoskeleton, structures of the cells.
Interactions of mitoxantrone with nucleic acids
in nucleus
Our previous results (Feofanov et al., 1997b) imply that
MITOX binds to ds nucleic acids by intercalation within the
nucleus. At the same time, the antitumor activity of MITOX
is suggested to be related to inhibition of topo II by stabi-
lization of the topo II-DNA cleavable complex (Smith et al.,
1990; D'Agra and Liu, 1989; Corbett and Osheroff, 1993)
as well as to the compaction and aggregation of chromatin
(Kapuscinski and Darzynkiewicz, 1986) rather than to DNA
intercalation itself. In our experiments the cells were treated
by MITOX in the logarithmic phase of the cell growth, in
which the expression and activity of the a-isoform of topo
II are the highest (Zini et al., 1994). It is known that the
170-kDa a-isoform of topo II is presumably distributed in
the perinucleolar region and at -2-fold lower density in the
nucleoli of K562 cells, whereas the 180-kDa ,3-isoform of
topo II is exclusively present in the nucleoli (Zini et al.,
1994). Therefore, some part of the MITOX-DNA com-
plexes detected by the CSI analysis should be involved in
formation of the ternary cleavable topo II-MITOX-DNA
complexes. These ternary complexes cannot be distin-
guished from binary MITOX-DNA complexes by spectral
fluorescence analysis, because their spectral parameters are
identical (Feofanov et al., 1997b). The relative amount of
the drug involved in the ternary cleavable complexes is
rather small as compared to the total amount of MITOX
bound with nucleic acids. It follows from the fact that
relatively low intranuclear concentration of MITOX results
in topo IT-related DNA damage (Smith et al., 1992). More-
over, the formation of the ternary cleavable complexes
reaches saturation at 1.25-2.5 ,iM extracellular concentra-
tions of the drug.
Our experiments reveal that amount of the drug bound to
nucleic acids continues to grow in cell nucleus without
saturation even when the cells are exposed to 10 ,uM of
MITOX (Table 2). It exceeds considerably the concentra-
tion when the formation of ternary cleavable complexes is
saturated. The continuous accumulation of MITOXNA has
to be accompanied by a dramatic increase in a drug/bp ratio
for intranuclear MITOX-DNA complexes and to result in
macro-destruction of nucleic acid conformation. From our
in vitro experiments (Feofanov et al., 1997b), unwinding of
the DNA helix has been shown to accompany binding of
MITOX to DNA, when the drugfbp molar ratio increases
from 1:100 to 1:5, eventually resulting in precipitation of
the drug-DNA complexes. Compaction and aggregation of
nuclear chromatin was observed by electronic microscopy
in the L1210 cells treated with MITOX (Kapuscinski and
Darzynkiewicz, 1986). In this sense, the evidence that high-
dose mitoxantrone induces programmed cell death or ap-
optosis (Bhalla et al., 1993) appears to be directly concerned
with the ability of MITOX to be accumulated thoroughly in
nuclear complexes with nucleic acids. MITOX-related dis-
ruption of the native structure of nucleic acids may activate
nuclear endonuclease and lead to fragmentation of genomic
DNA being a characteristic feature for apoptosis.
At present it is not clear whether advanced binding of
MITOX with hydrophobic cellular structures observed at
high drug concentrations is also associated to apoptosis
activation or it manifests appearance of additional drug
targets independent from apoptosis. In both cases the alter-
ation of the structure and/or normal functioning of cellular
cytoskeleton is speculated.
At high extracellular concentrations MITOX heavily ac-
cumulates within cancer cells, especially within the nucleus
in the form of complexes with nucleic acids. It predeter-
mines induction of additional mechanisms of cell killing, in
particular, apoptosis, which is sometimes more important
than inhibition of topo II. It is presumed to be very useful to
overcome cellular resistance to MITOX when it is origi-
nated from a low level of topo II or expression of mutant
topo II resistant to the drug. It is known that plasma con-
centrations of MITOX achieve a level from 1 to 10 ,um
(Ehninger et al., 1986), and high-dose drug regimes have
significant clinical activity in leukemias (Arlin et al., 1990;
Ehninger et al., 1986).
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